Association of cysteine-rich secretory protein 3 and β- microseminoprotein with outcome after radical prostatectomy Journal Article


Authors: Bjartell, A. S.; Al-Ahmadie, H.; Serio, A. M.; Eastham, J. A.; Eggener, S. E.; Fine, S. W.; Udby, L.; Gerald, W. L.; Vickers, A. J.; Lilja, H.; Reuter, V. E.; Scardino, P. T.
Article Title: Association of cysteine-rich secretory protein 3 and β- microseminoprotein with outcome after radical prostatectomy
Abstract: Purpose: It has been suggested that cysteine-rich secretory protein 3 (CRISP-3) and β-microseminoprotein (MSP) are associated with outcome in prostate cancer. We investigated whether these markers are related to biochemical recurrence and whether addition of the markers improves prediction of recurring disease. Experimental Design: Tissue microarrays of radical prostatectomy specimens were analyzed for CRISP-3 and MSP by immunohistochemistry. Associations between marker positivity and postprostatectomy biochemical recurrence [prostate-specific antigen (PSA) >0.2 ng/mL with a confirmatory level] were evaluated by univariate and multivariable Cox proportional hazards regression. Multivariable analyses controlled for preoperative PSA and pathologic stage and grade. Results: Among 945 patients, 224 had recurrence. Median follow-up for survivors was 6.0 years. Patients positive for CRISP-3 had smaller recurrence-free probabilities, whereas MSP-positive patients had larger recurrence-free probabilities. On univariate analysis, the hazard ratio for patients positive versus negative for CRISP-3 was 1.53 (P = 0.010) and for MSP was 0.63 (P = 0.004). On multivariable analysis, both CRISP-3 (P = 0.007) and MSP (P = 0.002) were associated with recurrence. The hazard ratio among CRISP-3-positive/MSP-negative patients compared with CRISP-3-negative/MSP-positive patients was 2.38. Adding CRISP-3 to a base model that included PSA and pathologic stage and grade did not enhance the prediction of recurrence, but adding MSP increased the concordance index minimally from 0.778 to 0.781. Conclusion: We report evidence that CRISP-3 and MSP are independent predictors of recurrence after radical prostatectomy for localized prostate cancer. However, addition of the markers does not importantly improve the performance of existing predictive models. Further research should aim to elucidate the functions of CRISP-3 and MSP in prostate cancer cells. © 2007 American Association for Cancer Research.
Keywords: immunohistochemistry; adult; controlled study; human tissue; treatment outcome; aged; middle aged; cancer surgery; unclassified drug; major clinical study; cancer localization; cancer recurrence; follow up; cancer diagnosis; neoplasm staging; prostate specific antigen; disease association; protein; recurrence; pathology; prostate cancer; prostatic neoplasms; oligonucleotide array sequence analysis; prostatectomy; multivariate analysis; tissue microarray; beta microseminoprotein; cysteine rich secretory protein 3; prostatic secretory proteins; seminal plasma proteins; salivary proteins
Journal Title: Clinical Cancer Research
Volume: 13
Issue: 14
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2007-07-15
Start Page: 4130
End Page: 4138
Language: English
DOI: 10.1158/1078-0432.ccr-06-3031
PUBMED: 17634540
PROVIDER: scopus
PMCID: PMC2660867
DOI/URL:
Notes: --- - "Cited By (since 1996): 25" - "Export Date: 17 November 2011" - "CODEN: CCREF" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Peter T Scardino
    671 Scardino
  2. William L Gerald
    375 Gerald
  3. Hans Gosta Lilja
    345 Lilja
  4. Andrew J Vickers
    884 Vickers
  5. Angel M Cronin
    145 Cronin
  6. James Eastham
    539 Eastham
  7. Samson W Fine
    462 Fine
  8. Victor Reuter
    1228 Reuter
  9. Scott Egon Eggener
    35 Eggener